MDS Virtual Congress 2021 Archives - Page 125 of 132

Pain and Non-Motor Symptoms in FXTAS

Y. Bronstein, N. Ashikian, M. Petrovic, A. Shah, I. Romanenko (Woodland Hills, USA)
Pain and symptom management in a case of cervical dystonia with comorbid generalized joint hypermobility using prolotherapy with osteopathic manipulative medicine

J. Mancini, D. Whitfield (Old Westbury, USA)
Pain in cervical dystonia: A meta-analysis of outcomes following treatment with abobotulinumtoxinA in randomized, controlled clinical studies

R. Rosales, L. Cuffe, B. Regnault, R. Trosch (Manila, Philippines)
Palliative care evaluation for movement disorders during COVID-19: Using Tele neurology to provide real-time care for an at risk Veterans Population.

N. Hack, K. Dalton (Rockville, USA)
Pallidal deep brain stimulation alters reward learning in segmental dystonia: a pilot study

A. Marcelino, A. Kühn, T. Gilbertston (Berlin, Germany)
Pallidal deep brain stimulation entrains finely tuned gamma oscillations in motor cortex

J. Anso, R. Gilron, M. Yaroshinsky, R. Wilt, R. Perrrone, I. Bledsoe, M. San Luciano, J. Ostrem, S. Little, C. de Hemptinne, P. Starr (San Francisco, USA)
Pallidal recordings in fully implanted dystonic patients: preliminary results

C. Palmisano, P. Capetian, Y. Thenaisie, A. Canessa, E. Moraud, M. Contarino, I. Isaias (Würzburg, Germany)
Pallidal single unit activity in cervical dystonia patients with unilateral deep brain stimulation

A. Sedov, A. Gamaleya, V. Popov, U. Semenova, S. Usova, A. Tomskiy, H. Jinnah, A. Shaikh (Moscow, Russian Federation)
Pallidal Stimulation in children with monogenic dystonia

A. Salazar Villacorta, M. Tardáguila, A. Bescós, K. Rosas, I. Delgado, L. Ispierto, R. álvarez, J. Muñoz, M. Poca, B. Pérez (Barcelona, Spain)
Paradoxical cerebral hyperperfusion in Parkinson’s disease with orthostatic hypotension

S-W. Yoo, J-S. Kim, K-S. Lee, S. Ha (Seoul, Republic of Korea)
PARK-BAND training program for Parkinson’s disease in clinical settings: A feasibility study.

D. Lima, J. Bonfadini, S. Almeida, E. Sobreira, P. Damasceno, M. Alencar, A. Viana-Júnior, J. Luna, P. Rodrigues, I. Pereira, A. Gadelha, P. Oliveira, E. Chaves, L. Oliveira, V. Gomes, R. Monteiro, T. Costa, L. Lima, M. Sobreira-Neto, P. Braga-Neto (Fortaleza, Brazil)
ParkAI – An AI Based Tool for Detection of Parkinson’s Disease using Vocal Measurements

SJS. Rajasekar, V. Narayanan, V. Perumal (Melmaruvathur, India)
Parkin Mutation and Deep Brain Stimulation

E. Erdil, H. Omercikoglu, F. Bayraklı, D. Gunal (Istanbul, Turkey)
Parkinson Disease with, but not without, Cognitive Decline Reveals Advanced Brain Aging

MC. Kuo, CL. Chen, RM. Wu, WY. Tseng (Taipei, Taiwan)
Parkinson Progression Marker Initiative – New Science/New Cohorts

K. Marek, A. Siderowf, T. Simuni, L. Chahine, K. Kieburtz, B. Mollenhauer, D. Galasko, K. Merchant, E. Brown, C. Coffey, R. Dobkin, T. Foroud, K. Poston, E. Flagg, S. Chowdhury, C. Tanner (New Haven, USA)
PARKINSON’S DISEASE AND COVID-19 PANDEMIC: MODIFICATIONS IN MOTOR AND NON-MOTOR SYMPTOMS AND IN THE ACCESS TO MEDICAL AND NON-MEDICAL CONSULTATIONS AND TREATMENTS

J. Bestoso, C V. Stefani, L. Ciancaglini, D. Bauso (Buenos Aires, Argentina)
Parkinson’s Families Project: analysis of a large cohort of patients with early onset and familial Parkinson’s disease

C. Towns, M. Tan, M. Pollard, S. Cable, L. Wu, R. Real, H. Morris (London, United Kingdom)
Parkinson’s rest tremor disappearance after cerebellar hemorrhage

L. Rebordão, A. Abreu, J. Peres (Amadora, Portugal)
Parkinson’s disease and Post-COVID-19 syndrome

V. Leta, M. Rodríguez-Violante, A. Abundes, K. Rukavina, J. Teo, C. Falup-Pecurariu, L. Irincu, S. Rota, R. Bhidayasiri, A. Storch, P. Odin, A. Antonini, K. Ray Chaudhuri (London, United Kingdom)
Parkinson’s Disease Clinical Progression in Latino Patients

A. Duarte Folle, C. Kusters, K. Paul, B. Ritz, M. Flores, J. Bronstein, A. Keener (Los Angeles, USA)
Parkinson’s Disease Functional Impacts Digital Instrument (PD-FIDI): Studies Preceding Clinical Validation

A. Pearlmutter, N. Wong, M. Levin, R. Zheng, R. Ellis, P. Kelly, M. Peterschmitt (Cambridge, USA)
Parkinson’s Disease Medication Safety in the Inpatient Cohort of a Tertiary Centre

A. Redmond, G. Richard, M. Penugonda, D. Bradley (Dublin 8, Ireland)
Parkinson’s disease patients may be at higher risk of Covid-19 mortality

M. Salari, M. Etemadifar, S. Tehrani Fateh, Z. Aminzade (Tehran, Islamic Republic of Iran)
Parkinson’s disease patients with hallucinations exhibit dopaminergic degeneration and cortical thinning

C. Wertz, K. Poston, N. Shaff, A. Hartman, A. Horner, A. Mayer, A. Vakhtin, A. Deligtisch, S. Pirio Richardson, S. Ryman (Albuquerque, USA)
Parkinson’s disease-linked LDL Receptor Related Protein 10 (LRP10) is implicated in regulation of the secretory and autophagy-lysosome pathways

A. Carreras Mascaro, MM. Grochowska, V. Boumeester, V. Bonifati, W. Mandemakers (Rotterdam, Netherlands)
Parkinson’s Disease, Cognitive Function and Health Literacy: A Problem with Shared Decision Making

O. Kaczmarek, A. Sethi, P. Tierney, B. Bumstead, M. Buhse, E. Kravis, B. Anand, M. Zarif, M. Gudesblatt (Patchogue, USA)
Parkinson’s Disease, Cognitive Function and Medication Management: A Problem in Routine Care

P. Tierney, O. Kaczmarek, A. Sethi, B. Bumstead, M. Buhse, E. Kravis, B. Anand, M. Zarif, M. Gudesblatt (Patchogue, USA)
Parkinson’s Disease, Cognitive Function: Exploration of the Relation of Multi-Domain Computerized Cognitive Testing and IADL (instrumental activities of daily living) and Neuro-QoL Upper Extremity Function (Fine Motor, ADL)

P. Tierney, O. Kaczmarek, A. Sethi, B. Bumstead, M. Buhse, E. Kravis, B. Anand, M. Zarif, M. Gudesblatt (Patchogue, USA)
Parkinson’s-disease risk variants are differentially associated with discrete phenotypic characteristics of Parkinson’s-disease at baseline.

B. Chase, A. Premkumar, B. Schoneburg, N. Kartha, J. Wei, H. Yu, A. Epshteyn, L. Garduno, A. Pham, R. Vazquez, R. Frigerio, D. Maraganore, K. Markopoulou (Skokie, USA)
Parkinsonism in a patient with limbic-predominant age-related TDP-43 encephalopathy (LATE) syndrome

C. Selvadurai, S. Schaefer (New Haven, USA)
Parkinsonism in individuals with genetic neurodevelopmental disorders: A systematic review

E. Scheibler, M. Kuijf, T. Koning, J. Zinkstok, A. Muller, T. Amelsvoort, A. Eeghen, E. Boot (Amersfoort, Netherlands)
Pathway to Parkinson’s Exercise Education Accreditation: Competencies for Exercise Professionals and Exercise Education Programs

L. Hoffman, M. Rafferty (New York, USA)
Patient and Care Partner Perspectives on a Community-Based Outpatient Palliative Care Intervention for Parkinson’s Disease and Related Disorders‬

M. Bock, R. Ayele, Z. Macchi, M. Dini, M. Katz, B. Kluger (San Francisco, USA)
Patient classification for adaptive deep brain stimulation

W. Chen, R. Gilron, S. Burden, B. Pepin, P. Starr (San Francisco, USA)
Patient-Reported Impact of Standard-of-Care: Change in Symptoms Following Dopamine Initiation and Deep Brain Stimulation

L. Mischley, C. Weaver, J. Farahnik, Y. Chien (Kenmore, USA)
Patterns and determinants of healthcare utilization among people with Parkinson’s disease: A population based analysis in Ontario, Canada

E. Crighton, A. Ouédraogo, M. Sawada, T. Mestre (Ottawa, Canada)
Patterns of Cortical Thinning in Patients with Parkinson’s Disease

H. Jergas, JC. Baldermann, JN. Petry-Schmelzer, H. Dafsari, V. Visser-Vanderwalle, T. Dembek, M. Barbe (Cologne, Germany)
Patterns of Improvement with Valbenazine in Patients with Tardive Dyskinesia

C. Correll, T. Carmack, C. Shah, L. Lundt (Glen Oaks, USA)
PD phenotype with premotor RBD is associated with a dysbiotic profile of gut microbiota.

V. Oppo, S. Vascellari, M. Melis, A. Manzin, G. Cossu (Cagliari, Italy)
People living with Parkinson’s disease during the COVID-19 Pandemic: A cross-sectional survey of the Canadian experience

M. Mckeown, T. Mestre, E. Crighton (Ottawa, Canada)
Perampanel as a treatment for Orthostatic Tremor

E. Vander Woude (Amsterdam, Netherlands)
Perampanel inhibits α-synuclein transmission in Parkinson’s disease models

J. Ueda, N. Uemura, R. Takahashi (Kyoto, Japan)
PERCEPTION OF INDIVIDUALS WITH PARKINSON´S DISEASE ABOUT ISOLATION DURING THE COVID-19 PANDEMIC

R. Pasquarelli Volpe, L. Laskovski, S. Mahmoud Smaili (Londrina, Brazil)
Peripheral immune profile and neutrophil-to-lymphocyte ratio in Parkinson’s disease

L. Muñoz-Delgado, D. Macías-García, S. Jesús, JF. Martin-Rodríguez, MA. Labrador-Espinosa, MV. Jiménez-Jaraba, A. Adarmes-Gómez, F. Carrillo, P. Mir (Sevilla, Spain)
Peripheral neuromodulation for the treatment of bladder symptoms associated with Parkinson’s disease

M. Smith, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)
Perivascular spaces in the basal ganglia and long-term motor prognosis in newly diagnosed Parkinson’s disease

SJ. Chung, YJ. Kim, PH. Lee, YH. Sohn (Yongin-Si, Republic of Korea)
Persistent and efficient transduction of the putamen following gene therapy for aromatic L-amino acid decarboxylase deficiency

Y. Onuki, S. Ono, T. Nakajima, K. Kojima, N. Taga, K. Kawai, T. Sato, S. Muramatsu, T. Yamagata (Yakushiji, Japan)
Personality dimensions could be predictive of quality-of-life outcome after deep brain stimulation of the sub-thalamic nucleus in Parkinson’s Disease

M. Boussac, T. Danaila, A. Eusebio, E. Hainque, JC. Corvol, O. Rascol, C. Moreau, AS. Rolland, D. Devos, S. Ansquer, OL. Boukbiza, AR. Marques, D. Maltete, S. Drapier, B. Jarraya, L. Belamri, P. Burbaud, M. Meyer, T. Rouaud, B. Giordana, M. Tir, C. Brefel-Courbon (Toulouse, France)
Perspectives of People with Parkinson Disease Managing Exercise during the COVID-19 Pandemic: A Qualitative Study

Q. Hanses, A. Yorke, J. Haines (Flint, USA)
Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy

T. Birnberg, L. Adar, W. Poewe, M. Bjornsson, M. Karlsson (Rehovot, Israel)
Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months

G. Corcoran, A. Karunakara, B. Vaughn, E. Brand-Schieber, T. Foltynie, R. Barker, S. Palfi (New York, USA)
Phenotype characteristics of ANO10 mutation carries: a case series from Serbia and a systematic review of the literature

I. Stankovic, N. Dragasevic, A. Milovanovic, AA. Marjanovic, M. Brankovic, V. Dobricic, I. Petrovic, M. Svetel, I. Novakovic, V. Kostic (Belgrade, Serbia)
Phenotype-genotype correlation in a case series from South Spain of Hereditary Spastic Paraplegia 7 (SPG7)

A. Adarmes Gómez, S. Jesús Maestre, D. Macias Garcia, L. Muñóz, F. Carrillo Garcia, M. Gómez Garré, P. Mir (Seville, Spain)
Physical activity (PA), patient reported outcomes and quality of life in Parkinson’s disease( PD)

J. Morley, I. Subramanian, J. Farahnik, L. Mischley (Philadelphia, USA)
Physical activity and cognitive functions in individuals with Parkinson’s disease

APC. Loureiro, VL. Israel, B. Yamaguchi (Curitiba, Brazil)
Physical activity and subjective perception of PD symptoms during COVID-19 lockdown: a clinical audit

V. Foster, J. Pasquini, N. Pavese (Newcastle Upon Tyne, United Kingdom)
PHYSICAL ACTIVITY AT HOME IS ABLE TO REDUCE THE WORSENING IN QUALITY OF LIFE IN PARKINSON’S DISEASE DURING COVID-19 PANDEMIC

I. Nascimento, C. Batista, D. Coelho, L. Almeida, A. Guimarães, A. Lindquist, V. Israel, H. Kanegusuku, R. Guimarães, N. Bosaipo, R. Barbosa, C. Correa, M. Finatto, F. Mendes, R. Azamor, M. Piemonte (São Paulo, Brazil)
Physical and mental fatigue in Parkinson’s Disease: analysis from COPPADIS database

MI. Morales-Casado, N. López-Ariztegui, A. Oliviero, V. Soto-León, JC. Segundo-Rodríguez, T. Deus Fonticoba, S. Jesús, M. Aguilar, P. Pastor, LL. Planellas, M. Cosgaya, J. García-Caldentey, N. Caballol, B. Vives, J. Hernández-Vara, I. Cabo, L. López-Manzanares, I. González-Aramburu, MA. ávila-Rivera, MJ. Catalán, V. Nogueira, V. Puente, M. Ruíz-de Arcos, C. Borrué, B. Solano-Vila, M. álvarez-Sauco, L. Vela, S. Escalante, E. Cubo, F. Carrillo-Padilla, JC. Martínez-Castrillo, P. Sánchez-Alonso, MG. Alonso-Losada, P. Clavero, J. Kulisevsky, M. Blázquez-Estrada, M. Seijo, J. Ruíz-Martinez, C. Valero, M. Kurtis, O. de Fábregues, J. González-Ardura, C. Ordás, L. López-Díaz, P. Mir, P. Martínez-Martín, D. Santos-García, C. Study Group (Toledo, Spain)
Piecing Together the Gut Microbiome in Parkinson’s Disease: A Meta-Analysis

TS. Toh, CW. Chong, SY. Lim, AH. Tan (Kuala Lumpur, Malaysia)
Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics

SS. Chiu, K. Terpstra, RK. Mishra (London, Canada)
Pilot study to assess gait-related motor symptoms in Parkinson’s disease by using a unique passive monitoring wearable technology

G. Monneret, D. Jacobs, L. Farid, A. Post, C. Moreau, G. Baille (Paris, France)
Pilot study to evaluate pimavanserin for the treatment of motor and behavioral symptoms of Tourette syndrome.

A. Billnitzer, J. Jankovic (Houston, USA)
PKG for the management of advance Parkinson’s Disease

S. Duja (Dudley, United Kingdom)
PLA2G6-Associated Neurodegeneration: A Continuum of Phenotypes

D. Shah-Zamora, M. Bailey (Chicago, USA)
Plasma and fecal short chain fatty acids as predictors for the risk and severity of Parkinson’s Disease

SJ. Chen, SY. Liao, YT. Lin, CH. Kuo, CH. Lin (Taipei City, Taiwan)
Plasma microRNA expression profiling in patients with progressive supranuclear palsy. A five-microRNA panel in plasma was identified as a potential biomarker for progressive supranuclear palsy

R. Yadav, P. Ramaswamy, P. Pal, R. Christopher (Bengaluru, India)
Plasma Neurofilament Light Chain Level and Orthostatic Hypotension in Early Parkinson Disease

DG. Park, JW. Kim, Y-S. An, J. Chang, JH. Yoon (Suwon, Republic of Korea)
Plasma phosphorylated α-synuclein relates to cognitive impairment in patients with Parkinson’s disease

N-N. Che (Nangjing, China)
Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson’s Disease

XQ. He, YW. Qian, SQ. Xu, Y. Zhang, CJ. Mo, XD. Yang, Q. Xiao (Shanghai, China)
Pooled efficacy and safety analysis of incobotulinumtoxinA for upper- and lower-limb spasticity in children with severe cerebral palsy (GMFCS levels IV–V)

P. Kaňovský, D. Gaebler-Spira, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, F. Heinen (Olomouc, Czech Republic)
Positive effect of Medical Cannabis in adults with Tourette syndrome

S. Anis, S. Arad, C. Zalomek, H. Shabtai, T. Taichman, N. Giladi, T. Gurevich (Tel Aviv, Israel)
Post-Covid-19 Parkinson’s disease: a Brazilian case series.

J. Tavares, D. Oliveira, S. Gaspar, C. Gomes, M. Neto, P. Neto (Fortaleza, Brazil)
Post-infectious Anti-GFAP-associated meningoencephalitis: A case report

T. Ahn, J. Joo (Seoul, Republic of Korea)
Post-stroke dystonia: Three unique cases

C. Han, L. Klebanoff, P. Magda, B. Sadoughi, S. Pullman, H. Sarva (Ny, USA)
Post-Traumatic Stress Disorder and risk of Parkinson’s Disease– 20 Years Follow-up real world data analysis

Y. Barer, G. Chodick, T. Gurevich (Tel Aviv, Israel)
Potential drug-drug interactions in hospitalized patients with Parkinson’s disease from tertiary center in Serbia

D. Aleksic, S. Stefanovic, M. Milosavljevic, J. Milosavljevic, S. Jankovic (Kragujevac, Serbia)
Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1

K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, D. Rukina, J. Anzures Cabrera, L. Essioux, M. Abt, B. van Lier, A. Thomann, H. Svoboda, W. Zago, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)
Precision Medicine in Neurodegeneration associated with Pantothenate kinase (PKAN) , its possible?

J. Abril Jaramillo (Seville, Spain)
Predicting MDS-UPDRS Ratings for Deep Brain Stimulation Patients Using Wearable Sensor Data

J. Watts, A. Khojandi, M. Niethammer, R. Ramdhani (Knoxville, USA)
Predictive factors of LCIG infusion therapy adherence – a single-center study of 103 consecutive LCIG patients

V. Viljaharju, T. Mertsalmi, KAM. Pauls, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)
Predictive value of UPSIT subsets in prodromal Parkinson disease

P. Vaswani, J. Morley, D. Jennings, A. Siderowf, K. Marek, P. Investigators (Philadelphia, USA)
Predictors of antidepressant and benzodiazepine treatment in Parkinson’s disease

G. Gentile, G. Zanotelli, L. Weis, R. Biundo, F. Sambataro, A. Antonini (Padua, Italy)
Predictors of Clinically Significant Quality of Life Impairment in Parkinson´s Disease. Results from the COPPADIS Cohort at 2 Years Follow-up.

D. Santos García, C. Cores, T. de Deus, J. Paz González, C. Martínez, E. Suárez, S. Jesús, M. Aguilar, P. Pastor, LL. Planellas, M. Cosgaya, J. García Caldentey, N. Caballol, I. Legarda, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, M. Avila, M. Catalán, V. Nogueira, V. Puente, M. de Arcos, C. Borrué, B. Solano, M. álvarez Sauco, L. Vela, S. Escalante, E. Cubo, F. Carrillo, J. Martínez Castrillo, P. Sánchez Alonso, M. Alonso Losada, N. López Ariztegui, E. Erro, J. Kulisevsky, M. Blázquez, M. Seijo, J. Ruíz Martínez, C. Valero, M. Kurtis, O. de Fábregues, J. González, C. Ordás, L. López Díaz, P. Mir, P. Martínez Martín (A Coruña, Spain)
Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)

D. Claassen, R. Ayyagari, V. Garcia-Horton, S. Zhang, S. Leo (Nashville, USA)
Predictors of survival in Progressive Supranuclear Palsy in a Tunisian cohort

A. Neji, A. Nasri, I. Sghaier, S. Mrabet, M. Bendjebara, I. Kacem, R. Gouider (Tunis, Tunisia)
Preliminary validation of an educational handbook for Parkinson’s disease patients in Brazil

J. Bonfadini, D. Lima, A. Carneiro, S. Almeida, M. Rocha, M. Porto, P. Braga-Neto (Fortaleza, Brazil)
Preoperative EEG-based Machine Learning predicts cognitive deterioration after STN DBS in Parkinson’s Disease patients

V. Geraedts, M. Koch, R. Kuiper, M. Kefalas, T. Bäck, J. van Hilten, H. Wang, H. Middelkoop, N. vd Gaag, MF. Contarino, M. Tannemaat (Leiden, Netherlands)
Prevalence and Clinical Characteristics of Autosomal Dominant Spinocerebellar Ataxia in a Large Canadian Cohort from Ontario

R. Munhoz, E. Slow, S. Alshimemeri (Toronto, Canada)
Prevalence of advanced Parkinson’s disease in Thai patients with Parkinson’s disease using The Consensus on the Definition of Advance Parkinson’s disease (CEPA Study): A single-center study

K. Thanapermpool, J. Srikajon, Y. Pitakpatapee, W. Saengphatrachai, T. Sangpeamsook, T. Wangthumrong, A. Pisarnpong, P. Srivanitchapoom (Bangkok, Thailand)
Prevalence of Essential Tremors in Rural Gujarat, India

A. Chin, S. Arora, S. Raithata, D. Desai, U. Shah, A. Deb, S. Desai (Worcester, USA)
PREVALENCE OF MOVEMENT DISORDERS AT A TERTIARY HEALTH CARE CENTRE IN ABUJA, NIGERIA

N. Obianozie, G. Onwuegbuzie, P. Alabi, F. Abdulai (Gwagwalada, Nigeria)
Prevalence of neurogenic orthostatic hypotension in the idiopathic Parkinson Progression Marker Initiative cohort.

P. Beach, J. Mckay (Atlanta, USA)
Prevalence of Parkinsonism and Parkinson Disease in urban and rural populations in Latin America.

J. Llibre-Guerra, M. Prina, A. Sosa, D. Acosta, I. Jimenez-Velasquez, M. Guerra, A. Salas, A. Rodriguez-Salgado, J. Llibre-Guerra, G. Peters, I. Acosta, J. Juncos, J. Llibre-Rodriguez (La Habana, Cuba)
Prevalence of Restless Legs Syndrome in the South African population

J. Bourne, C. Dafkin, S. Kerr (Johannesburg, South Africa)
Prevalence of Suicidal Ideation and Associated Clinical Features in Lewy Body Dementia

K. Moore, M. Armstrong, C. Jacobson, N. Gamez, B. Patel, J. Sullivan (Gainesville, USA)
Preventing falls in Parkinson’s disease by re-educating reactive and planned foot placement accuracy through a multi-sensory approach. 3 cases.

D. Schlosser, Z. Mari (Las Vegas, USA)
Primary Palliative Care for Huntington Disease

M. Harrison, D. Morrissey, F. Daly (Charlottesville, VA, USA)
Problems faced by Parkinson’s disease patients during COVID-19 pandemic compulsory lockdown and its management with the help of Telemedicine in a North Indian cohort

K. Shukla, N. Sawal (Chandigarh, India)
Prognostic Modeling of Parkinson’s Disease Progression Using Early Longitudinal Patterns of Change

X. Ren, J. Lin, G. Stebbins, C. Goetz, S. Luo (Foster City, CA, USA)
Progression of brain atrophy in Parkinson’s disease is shaped by connectome and local vulnerability

C. Tremblay, S. Rahayel, A. Vo, F. Morys, G. Shafiei, R. Markello, Z. Gan-Or, B. Misic, A. Dagher (Montreal, Canada)
Progression of neuroinflammation in patients with isolated REM sleep behavior disorder. A 11C-PK11195 PET study

A. Baun, K. Stær, A. Iranzo, M. Stokholm, K. østergaard, M. Serradell, M. Otto, K. Svendsen, A. Garrido, D. Vilas, J. Santamaria, A. Møller, C. Gaig, D. Brooks, P. Borghammer, E. Tolosa, N. Pavese (Aarhus, Denmark)
Progression of nigro-striatal denervation in cerebellar Multiple System Atrophy: a prospective study

T. Wirth, I. Namer, B. Monga, C. Bund, A. Iosif, O. Gebus, S. Montaut, T. Bogdan, L. Robelin, M. Renaud, S. Kremer, C. Tranchant, M. Anheim (Strasbourg, France)
Progression of nigrostriatal dysfunction in Parkinson’s disease: a longitudinal multimodal PET study

K. Steidel, M. Ruppert, A. Greuel, M. Tahmasian, F. Maier, J. Hammes, T. van Eimeren, L. Timmermann, M. Tittgemeyer, A. Drzezga, D. Pedrosa, C. Eggers (Marburg, Germany)
Progression of Syndrome Specific Metabolic Brain Patterns in Patients with Various Parkinsonian Syndromes

M. Perovnik, K. Krejan, P. Tomše, E. Rebec, U. Simončič, L. Jensterle, L. Ležaić, M. Trošt (Ljubljana, Slovenia)
Progressive and delayed onset hyperglycemic chorea after blood glucose normalization: A case report

C. Wantaneeyawong, C. Teekaput, K. Booncharoen (Chiang Mai, Thailand)
Progressive Ataxia with Palatal Tremor in a Metal Worker with Possible Osmotic Demyelination

I. Goldszer, S. Merchant (Charleston, USA)
Progressive changes in laryngeal posturing and dynamics as biomarkers of progression in Parkinson’s disease

A. Ma, D. Thyagarajan, K. Lau (Melbourne, Australia)
Progressive encephalomyelitis with rigidity and myoclonus in a Mexican patient

R. Garcia-Bermudez, D. Leon-Castillo, B. Bertado-Cortes (Mexico City, Mexico)
Progressive Gait Disturbance presumed to be caused by idiopathic peripheral neuropathy: A case of Normal Pressure hydrocephalus.

K. Dalton, N. Hack (Bethesda, USA)
Promising Biomarkers for Task Specific Dystonia

S. Merchant, M. Hallett (Charleston, USA)
Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease

J. Gamez, M. Calopa, E. Muñoz, A. Ferré, O. Huertas, K. Mcallister, N. Reig, C. Scart-Grès, R. Insa, J. Kulisevsky (Barcelona, Spain)
PROPRIOSPINAL MYOCLONUS ASSOCIATED TO SARS-COV-2 RESPIRATORY INFECTION

JL. Chico-Garcia, M. Villadoniga, I. Regidor-Bailly Baillieri, A. Caballero, A. Beltran-Corbellini, P. Parra-Diaz, F. Rodriguez-Jorge, A. Alonso-Canovas, JC. Martinez-Castrillo, I. Corral-Corral (Madrid, Spain)
Providing Genetic Testing and Genetic Counseling to the Parkinson’s Disease Community: the PD GENEration Pilot Study Experience

L. Cook, J. Verbrugge, J. Schulze, T. Schwantes-An, A. Chan, J. Beck, A. Naito, A. Hall, K. Marder, M. Nance, M. Schwarzschild, T. Simuni, A-M. Wills, R. Alcalay (Indianapolis, USA)
PSYCHODYNAMIC THERAPY GROUPS FOR RELATIVES AND CAREGIVERS IN THE CONTEXT OF A PD PROGRAM

L. Aguerre, E. Cortinas, M. Martinovic, G. Montado (Montevideo, Uruguay)
Psychogenic movement disorders precipitated by post-lockdown return to school in adolescents: case series from Kenya

D. Sokhi, K. Oyieke, P. Samia (Nairobi, Kenya)
Pyramidal pathway changes at conventional brain 3T-MRI in patients with hereditary spastic paraplegia

G. Rizzo, S. Battaglia, AF. Marliani, L. Albini Riccioli, V. Vacchiano, S. de Pasqua, P. Avoni, I. Bartolomei, F. Salvi, R. Liguori (Bologna, Italy)